Xeris Biopharma Holdings, Inc.XERSNASDAQ
Loading
R&D Expenses Over TimeExpanding
Percentile Rank78
3Y CAGR+14.1%
5Y CAGR+8.3%
Year-over-Year Change
Research and development spending
3Y CAGR
+14.1%/yr
vs -15.3%/yr prior
5Y CAGR
+8.3%/yr
Recent acceleration
Acceleration
+29.4pp
Accelerating
Percentile
P78
Within normal range
vs 5Y Ago
1.5x
Solid growth
Streak
3 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $31.16M | +21.9% |
| 2024 | $25.56M | +14.4% |
| 2023 | $22.34M | +6.6% |
| 2022 | $20.97M | -16.7% |
| 2021 | $25.16M | +20.3% |
| 2020 | $20.92M | -65.4% |
| 2019 | $60.44M | +48.7% |
| 2018 | $40.65M | +101.6% |
| 2017 | $20.17M | +97.0% |
| 2016 | $10.24M | - |